Breast Cancer

Latest News

Health equity text | Image Credit: Andrii - stock.adobe.com
Racial Inequities in Guideline-Adherent Breast Cancer Care and Timely Treatment

November 19th 2024

Older non-Hispanic Black adults with early-stage breast cancer are less likely to receive timely treatment and guideline-concordant care, increasing their risk of death compared with non-Hispanic White women.

Medicare Expansion | Image Credit: wladimir1804- stock.adobe.com
Breast Cancer Outcomes Improved in States With Medicaid Expansion

October 24th 2024

FDA Approved
FDA Approves Inavolisib in Locally Advanced, Metastatic Breast Cancer

October 11th 2024

Breast screening | Image Credit: Valerii Apetroaiei - stock.adobe.com
5 Things to Know Before a Breast Screening

October 11th 2024

Michael Hassett, MD, MPH, Dana-Farber Cancer Institute
Advancing Breast Cancer Care With HER2-Targeted Therapies

October 10th 2024

Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.

Watch the latest AJMC Peer Exchange on Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

More News

Pivotal Studies for CDK4/6 Inhibitors
September 2nd 2020

Pivotal Studies for CDK4/6 Inhibitors

First-line Therapy for HR-Positive, HER2-Negative mBC
September 2nd 2020

First-line Therapy for HR-Positive, HER2-Negative mBC

Value-Based Care vs Cost of Treatment for mBC
September 2nd 2020

Value-Based Care vs Cost of Treatment for mBC

Provider Responsibility to Cost Burden for mBC Therapy
September 2nd 2020

Provider Responsibility to Cost Burden for mBC Therapy

Patient Cost Burden for Metastatic Breast Cancer Therapy
September 2nd 2020

Patient Cost Burden for Metastatic Breast Cancer Therapy

Provider Perspective on Value-Based Care for mBC
September 2nd 2020

Provider Perspective on Value-Based Care for mBC

Patient, Advocate, and Payer on Value-Based Care for mBC
September 2nd 2020

Patient, Advocate, and Payer on Value-Based Care for mBC

Patient Journey and Development of Metastatic Breast Cancer
September 2nd 2020

Patient Journey and Development of Metastatic Breast Cancer

Age a Leading Factor in COVID-19–Related Breast Cancer Treatment Delays
August 31st 2020

Age a Leading Factor in COVID-19–Related Breast Cancer Treatment Delays

Maggie L. Shaw
Questionnaire results from the first weeks of the coronavirus disease 2019 (COVID-19) pandemic show that breast cancer treatment delays happened more often for younger vs older women.
Being Each Other’s Hero: Facing MBC Together
August 25th 2020

Being Each Other’s Hero: Facing MBC Together

Maggie L. Shaw
At diagnosis, approximately 6% of breast cancers are metastatic breast cancer (MBC), which although treatable is not curable. Experts predicted that 276,480 women and 2620 men would receive such a diagnosis in 2020.
Anti-inflammatory Diet May Help Postmenopausal Breast Cancer Survival
August 23rd 2020

Anti-inflammatory Diet May Help Postmenopausal Breast Cancer Survival

Maggie L. Shaw
Risks of all-cause mortality and breast cancer-specific mortality decreased when female patients followed a more anti-inflammatory diet after their diagnosis of postmenopausal invasive breast cancer.
Study Shows Paclitaxel, Carboplatin Effective Against Triple-Negative Breast Cancer
August 18th 2020

Study Shows Paclitaxel, Carboplatin Effective Against Triple-Negative Breast Cancer

Maggie L. Shaw
The Adjuvant Platinum and Taxane in Triple-Negative Breast Cancer trial investigated this combination adjuvant treatment vs the standard-of-care anthracycline plus docetaxel among patients with operable disease.
center for biosimilars
August 17th 2020

Choice Is Vital to Biosimilar Savings Picture, Panelists Say

Tony Hagen
The challenges of complying with payer mandates in biosimilars were discussed in a webinar sponsored by The American Journal of Managed Care® and The Center for Biosimilars®.
Screening for Breast Cancer at Younger Ages Linked to Reduced Mortality
August 14th 2020

Screening for Breast Cancer at Younger Ages Linked to Reduced Mortality

Maggie L. Shaw
Screening women aged 40 to 49 years for breast cancer reduced mortality by 25% in the first 10 years compared with waiting until at age 50 years and older, which is the common practice in the United Kingdom.
Are There Benefits to Awake Breast Cancer Surgery During COVID-19?
August 11th 2020

Are There Benefits to Awake Breast Cancer Surgery During COVID-19?

Maggie L. Shaw
In Italy, a study looked at reallocating resources meant for patients with breast cancer to those stricken with coronavirus disease 2019, finding that the former could benefit from fast-track awake surgery to reduce risk of cross-infection.
Survival Consistent for Women With Early-Stage Breast Cancer Despite Surgery Delays
August 7th 2020

Survival Consistent for Women With Early-Stage Breast Cancer Despite Surgery Delays

Maggie L. Shaw
Delays in surgery to treat early-stage breast cancer and receiving neoadjuvant endocrine therapy did not decrease survival odds among female patients, authors report in the Journal of the American College of Surgeons.
Global Incidence of Premenopausal, Postmenopausal Breast Cancer Rising
August 3rd 2020

Global Incidence of Premenopausal, Postmenopausal Breast Cancer Rising

Maggie L. Shaw
Higher-income countries are seeing their rates of premenopausal breast cancer increase faster, whereas cases of postmenopausal breast cancer are increasing in number faster in lower-income studies.
Mortality Among Men With Breast Cancer Decreases With Adjuvant Chemotherapy
July 30th 2020

Mortality Among Men With Breast Cancer Decreases With Adjuvant Chemotherapy

Maggie L. Shaw
Less than 1% of all breast cancers occur in men, making this a rare disease among that patient population, and most treatment guidelines are based on outcomes and survival rates seen in women with the disease.
Women With Extremely Dense Breast Tissue May Not Benefit From 3-D Mammography
July 28th 2020

Women With Extremely Dense Breast Tissue May Not Benefit From 3-D Mammography

Maggie L. Shaw
Compared with digital mammography, digital breast tomosynthesis, also called 3-dimensional (3-D) mammography, has been proven superior at effectively detecting breast cancer and leading to fewer recall visits, but more information is needed for how subgroups of women with different breast densities benefit from the screening method, especially those classified as having extremely dense breast tissue.
Germline BRCA-Mutated Breast Cancer Does Not Increase Risk of Adverse Pregnancy Outcomes
July 23rd 2020

Germline BRCA-Mutated Breast Cancer Does Not Increase Risk of Adverse Pregnancy Outcomes

Maggie L. Shaw
Women with early-onset germline BRCA-mutated breast cancer can have subsequent pregnancies without increasing their risk for disease recurrence, according to the authors of a recent study in Journal of Clinical Oncology.
Diagnostic Delays From COVID-19 May Increase Cancer-Related Deaths, UK Studies Say
July 21st 2020

Diagnostic Delays From COVID-19 May Increase Cancer-Related Deaths, UK Studies Say

Maggie L. Shaw
The next several years could bear witness to thousands of additional deaths from cancer that could have been prevented through routine diagnostic care that was delayed because of the coronavirus disease 2019 (COVID-19) pandemic, according to a pair of studies in The Lancet Oncology.
Male Breast Cancer Survival Similar to That in Women Despite Treatment Variation
July 17th 2020

Male Breast Cancer Survival Similar to That in Women Despite Treatment Variation

Maggie L. Shaw
Because male breast cancer is such a rare disease, few strides have been made that convey advantages in its detection, incidence, and mortality. Most treatment guidelines have been extracted from studies performed among female patients.
Interval Breast Cancer Found Within 1 Year Linked to Worse Mortality
July 14th 2020

Interval Breast Cancer Found Within 1 Year Linked to Worse Mortality

Maggie L. Shaw
Breast cancer diagnosed in the year following a negative result after a mammogram has now been associated with an increase in mortality compared with breast cancer detected at a screening, report JAMA Network Open study results.
Smoking History May Influence Adverse Outcomes Following Radiotherapy for Breast Cancer
July 9th 2020

Smoking History May Influence Adverse Outcomes Following Radiotherapy for Breast Cancer

Maggie L. Shaw
Smoking history can both increase the risk of cancer and create a hypoxic environment within the body, leading to poor outcomes, including less-effective treatment, among patients who undergo radiotherapy.
Can Early Screening Reduce Breast Cancer Mortality Among Childhood Cancer Survivors?
July 7th 2020

Can Early Screening Reduce Breast Cancer Mortality Among Childhood Cancer Survivors?

Gianna Melillo
In survivors of childhood cancer, early initiation of annual breast cancer screening with MRI, with or without mammography, may reduce breast cancer mortality by half or more, according to a study published in Annals of Internal Medicine.
Study Results Show Possible Link Between Medicaid Expansion, Drop in Advanced Breast Cancer
July 1st 2020

Study Results Show Possible Link Between Medicaid Expansion, Drop in Advanced Breast Cancer

Maggie L. Shaw
Despite ongoing disparities in the use of health care services among races/ethnicities and ages, as well as by insurance status, African American women with advanced breast cancer benefited the most following implementation of the Affordable Care Act in states that chose to expand Medicaid coverage.
Closing Thoughts on Metastatic Breast Cancers
July 1st 2020

Closing Thoughts on Metastatic Breast Cancers

Assessing the Value of Personalized Treatment in mBC
July 1st 2020

Assessing the Value of Personalized Treatment in mBC

Considerations for NGS Testing in mTNBC
July 1st 2020

Considerations for NGS Testing in mTNBC

Treatment Options in Metastatic TNBC
July 1st 2020

Treatment Options in Metastatic TNBC

<1
...
456789101112>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo